8-K: Invivyd Refiles 2022 Financials, Cites Going Concern Uncertainty

Invivyd Inc. refiled its 2022 financial statements due to concerns about its ability to continue as a going concern, despite having sufficient funds into the fourth quarter of 2024.

Summary

• Invivyd Inc. has refiled its consolidated financial statements for the year ended December 31, 2022, originally filed on March 23, 2023.
• The refiling includes an update to Note 1, disclosing substantial doubt about the company's ability to continue as a going concern.
• This doubt arises because the company's existing cash and cash equivalents are projected to be sufficient only into the fourth quarter of 2024, excluding any revenue or external financing.
• The company has been incurring recurring losses since its inception and will require additional funding to finance future operations.
• The refiled financial statements are otherwise identical to the original filing and do not reflect any events or occurrences after the original filing date.

Sentiment

Score: 3

Explanation: The document expresses significant concerns about the company's financial viability, with a going concern warning and the need for additional funding. This indicates a negative outlook from an investment perspective.

Positives

• The company believes its current cash will fund operations into the fourth quarter of 2024.
• The company is actively working with regulatory agencies to streamline development and commercialization plans for novel antibodies.

Negatives

• There is substantial doubt about the company's ability to continue as a going concern.
• The company has incurred recurring losses since its inception.
• The company has an accumulated deficit of $533.4 million as of December 31, 2022.
• The company will require additional funding to continue operations beyond the fourth quarter of 2024.
• The company has not generated any revenue since inception.

Risks

• The company's ability to continue as a going concern is in doubt due to insufficient cash beyond the fourth quarter of 2024 without additional funding.
• The company may not be able to obtain financing on acceptable terms, or at all.
• Failure to secure additional funding could force the company to delay, reduce, or eliminate research and development programs.
• The company is dependent on a limited number of third parties for manufacturing and license rights.
• The COVID-19 pandemic continues to impact the company's operations and commercial prospects.

Future Outlook

The company believes its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2024, excluding any contribution from revenues or external financing. The company will require additional funding through a combination of revenues, equity offerings, grants, debt financings, or collaborations to finance its future operations.

Management Comments

• Based on current operating plans and excluding any contribution from revenues or external financing, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2024.
• As such, excluding any contribution from revenues or external financing, the Company will not have sufficient cash and cash equivalents to fund its operating expenses and capital requirements beyond one year from the reissuance of these consolidated financial statements on February 9, 2024, and therefore, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.

Industry Context

The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and the need for significant capital investment. Invivyd's situation is not uncommon for early-stage companies in this sector, particularly those focused on novel therapies. The company's focus on antibody-based therapies for viral threats aligns with current trends in infectious disease research.

Comparison to Industry Standards

• Invivyd's cash burn rate is significant, with a net loss of $241.3 million in 2022, which is typical for a clinical-stage biotech company but highlights the need for substantial funding.
• Compared to companies like Moderna or BioNTech, which have generated substantial revenue from their COVID-19 vaccines, Invivyd is still in the development phase and has not yet generated revenue.
• Other companies in the antibody therapeutics space, such as Regeneron or Eli Lilly, have established revenue streams from approved products, which provides a more stable financial base.
• The going concern warning is a significant concern, as it indicates that the company's current financial resources are not sufficient to sustain operations without additional funding, which is a risk that many early-stage biotech companies face.
• The company's reliance on Adimab for technology and research is similar to other biotech companies that rely on strategic partnerships, but it also introduces a dependency risk.

Management Changes

Legal Proceedings

• A securities class action lawsuit was filed against the company and certain of its former officers on January 31, 2023, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5.
• The company received a request from the SEC, dated March 22, 2023, for documents and information concerning, among other matters, the company's testing and analysis of the efficacy of ADG20 against Omicron and other COVID-19 variants.

Related Party Transactions

• Adimab participated in the Series B and Series C Preferred Stock financings.
• The company has ongoing agreements with Adimab for research and development services, including the Adimab Assignment Agreement, Adimab Collaboration Agreement, and Adimab Platform Transfer Agreement.
• The company has a Master Services Agreement with Population Health Partners, L.P., where two board members are managing partner and partner, respectively.

Stakeholder Impact

• Shareholders face significant risk due to the going concern uncertainty and the need for additional funding.
• Employees may be concerned about job security given the company's financial situation.
• Customers and partners may be hesitant to engage with the company due to the uncertainty surrounding its future.
• Creditors may be concerned about the company's ability to repay debts.

Next Steps

• The company will need to secure additional funding to continue operations beyond the fourth quarter of 2024.
• The company will continue to work with regulatory agencies to streamline development and commercialization plans for novel antibodies.
• The company will need to address the concerns raised by the independent auditor regarding its ability to continue as a going concern.

Key Dates

Keywords

going concern, financial statements, refiling, cash equivalents, operating expenses, funding, biopharmaceutical, research and development, COVID-19, antibodies